Bionano Genomics stock price target lowered to $6 by H.C. Wainwright
H.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.
How this was made
The 30-second read
Why it matters
The lowered price target reflects short-term valuation adjustments; long-term prospects depend on execution of growth strategies.
Market read
The news is relevant for investors focusing on biotech and genomics sectors, especially those holding or considering Bionano Genomics shares.
What to watch
Potential upcoming catalysts, such as new product launches or partnerships, could offset current concerns and lead to upside surprises.
Background
Bionano Genomics reported revenue declines for Q4 2025 and full year 2025, but provided optimistic guidance for 2026, indicating potential growth despite recent setbacks.
Ticker impact
The news directly pertains to Bionano Genomics (NASDAQ:BNGO), affecting its stock outlook.
Potential short-term decline followed by stabilization or slight rebound as fundamentals remain positive.
The downward price target suggests caution; however, the maintained Buy rating and positive revenue guidance indicate long-term potential. Technical levels near recent lows may support a rebound.
Market effects
The biotech and genomics sector may experience slight negative sentiment due to valuation adjustments.
Limited regional impact; primarily affecting North American biotech stocks.
Low; specific to Bionano Genomics and related sector.
Counterpoint
The revenue decline and increased share count could indicate underlying operational challenges, suggesting a cautious approach.
Key entities
- CompanyBionano Genomics
A biotech firm specializing in genome analysis tools.
- Analyst FirmH.C. Wainwright
An investment bank providing research and analysis on biotech stocks.
